AEON Biopharma
AEON
73 hedge funds and large institutions have $192M invested in AEON Biopharma in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 4 closing their positions.
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
24% more funds holding
Funds holding: 59 → 73 (+14)
12% more capital invested
Capital invested by funds: $172M → $192M (+$20.2M)
0.2% more ownership
Funds ownership: 0.79% → 0.99% (+0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$6.57M |
| 2 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$4.51M |
| 3 |
Millennium Management
New York
|
+$3.74M |
| 4 |
JP Morgan Chase
New York
|
+$2.67M |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$2.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.92M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.44M |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$1.72M |
| 4 |
SC
Sculptor Capital
New York
|
-$1.46M |
| 5 |
CL
CSS LLC
Chicago,
Illinois
|
-$1.28M |
AEON Hedge Fund Activity: Q4 2021 in Review
73 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2021, worth a combined $192M — up 12% from $172M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AEON positions and 4 closed out — a net gain of 14 holders — while 14 added to existing stakes and 6 trimmed.
The largest buyer was Marshall Wace, adding an estimated $6.57M. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $2.92M sold.
- 73 institutional investors held AEON Biopharma (AEON) as of Q4 2021, up from 59 in Q3 2021.
- Funds reported $192M of AEON Biopharma stock for Q4 2021, up 12% quarter-over-quarter.
- 18 funds opened new AEON Biopharma positions in Q4 2021 and 4 closed out, a net change of +14 holders.
- The largest AEON Biopharma buyer in Q4 2021 was Marshall Wace, an estimated $6.57M added.
- The largest AEON Biopharma seller in Q4 2021 was Polar Asset Management Partners, an estimated $2.92M sold.
Based on aggregated 13F filings for Q4 2021.